{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 49,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/38",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.46,
        "x": 0.04,
        "y": 0.082
      },
      "kind": "callout",
      "text": "Designed to show overall survival benefit given CAEL-101 targeted MoA to bind and clear amyloid fibrils",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "344ab601-6216-46b4-b265-a58406feb0f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.44,
        "x": 0.52,
        "y": 0.082
      },
      "kind": "callout",
      "text": "First-and-only medicine for both Stage IIIa and IIIb AL amyloidosis patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5eae1baa-669e-42ec-a206-a5dbc0d1f4c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.46,
        "x": 0.04,
        "y": 0.24
      },
      "kind": "diagram",
      "text": "Phase III CAEL-101 twin study design flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "089d6bf4-710b-499b-9d10-7a846126b470",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Risk factors include cTnT and NT-proBNP. AL amyloidosis = light-chain amyloidosis; PCD = plasma cell dyscrasia; QW = once-weekly; IV = intravenous; Q2W = every 2 weeks; MoA = mechanism of action; OS = overall survival; HLR = high-level results.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "845aee97-6a7e-4aab-a8e6-803aa05f5475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.44,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "table",
      "text": "Risk factors and median OS by disease stage",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fed6739e-9c5a-4159-9b48-e0d387feec1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Tailored to address mortality cause by removing amyloid fibrils, improving overall survival",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "353d2725-2e2e-4747-be33-057236ca877e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "CAEL-101 in AL amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04bf1bbc-4303-4567-b3c5-2a10158bffa6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 49,
      "from": 30,
      "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}